Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-313 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-313.
Tmax of ABBV-313.
Beta of ABBV-313.
t1/2 of ABBV-313.
AUCt of ABBV-313.
| Arm | Type | Description |
|---|---|---|
| Part 1, Group 1: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 2: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 3: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 4: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 5: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 6: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 2, Group 7: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive multiple doses of ABBV-313 or Placebo |
| Part 2, Group 8: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive multiple doses of ABBV-313 or Placebo |
| Name | Type | Description |
|---|---|---|
| ABBV-313 | DRUG | Injection |
| Placebo | DRUG | Injection |
Inclusion Criteria: * BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, v...
ABBV-313 is an investigational small molecule drug being developed by AbbVie Inc. It is in Phase 1 clinical development and is currently being studied in healthy adult volunteers in the United States. Its therapeutic indication has not been disclosed.
ABBV-313 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the ongoing Phase 1 study of the compound.
ABBV-313 is in Phase 1 clinical development. It has not been approved by the FDA and remains investigational. One Phase 1 trial is currently recruiting, and no trials of ABBV-313 have been completed.
ABBV-313 is being evaluated in one Phase 1 trial, NCT07673120, titled a study to assess safety, tolerability, and how single and multiple injections or infusions of ABBV-313 affect the body of adult participants. The trial is recruiting 64 healthy volunteers in the United States.
The Phase 1 trial NCT07673120 is a randomized, double-blind, controlled study enrolling 64 healthy adult volunteers aged 18 years and older in the United States. It evaluates single and multiple injections or infusions of ABBV-313, assessing safety, tolerability, and how the drug affects the body.